10.78MMarket Cap-306P/E (TTM)
0.350High0.330Low299.77KVolume0.340Open0.350Pre Close101.90KTurnover1.22%Turnover RatioLossP/E (Static)30.88MShares9.37252wk High0.70P/B8.60MFloat Cap0.33052wk Low--Dividend TTM24.64MShs Float26.750Historical High--Div YieldTTM5.71%Amplitude0.330Historical Low0.339Avg Price1Lot Size
Vincerx Pharma Stock Forum
Vincerx Reports Positive Initial Clinical Data From Ongoing Vip943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx™ Platform technology
Vincerx focusing resources on continued development of VIP943
Expected cash runway into early 2025
Managemen...
NEWS
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
No comment yet